F-X. Danlos - 1Departement d’Innovation Therapeutique et d´Essais Precoces (DITEP), Institut Gustave Roussy

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 30 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

657P Prospective Validation of the T Cell Engager (TCE) Score in Patients Treated with Bispecific CD3 TCE Antibodies in Phase I Clinical Trials

N. Herbel,K. Ouali,F-X. Danlos, C.P. Massard, V. Goldschmidt,J-M. Michot,A. Laparra,A. Bernard-Tessier, A. Gazzah, R. Bahleda, A. Hollebecque,C. Henon,S. Postel-Vinay, Y. Loriot, V. Ribrag, A. Marabelle, K. Fizazi,S. Ponce Aix,S. Champiat, C. Baldini

Annals of Oncology (2024)

引用0浏览0引用

661P Safety and Activity of CY-101 in Patients with Advanced Solid Tumors: the Phase I/IIa CICILIA Trial

B.J. Sikkema,S. Champiat,E.H. Gort,F-X. Danlos,V. Moreno Garcia,F. Opdam, H. Gelderblom,M. Chaney,L. Prestegarden,F.A. Eskens

Annals of Oncology (2024)

引用0浏览0引用

Risks and Benefits of Phase 1 Clinical Trials for Patients with Relapsed or Refractory Lymphoma, from 2008 to 2023

Jean‐Marie Michot,Marta Guerra,Cyril Quivoron,Linda Mahjoubi,Emily Alouani,Kaïssa Ouali,Claudia Parisi,F-X. Danlos,Vincent Goldschmidt,Clémence Hénon,Capucine Baldini, S. Ponce,Vincent Ribrag

Hematological oncologyno. S2 (2023): 600-601

引用0浏览0引用

86P Validation of the Gustave Roussy Immune (grim) Score in Patients Treated with Bispecific CD3 T Cell Engagers in Phase I Clinical Trials

N. Herbel,V. Goldschmidt,J-M. Michot,A. Laparra,A. Géraud,K. Ouali,F-X. Danlos,P. Martin Romano,P. Vuagnat,A. Bernard-Tessier,A. Gazzah,R. Bahleda,A. Hollebecque,A. Marabelle,S. Postel-Vinay,C. Massard,V. Ribrag,S. Ponce Aix,S. Champiat,C. Baldini

ESMO openno. 1 (2023): 100944-100944

引用0浏览0引用

85P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials

A. Mavrikios,C. Baldini,Y. Loriot,S. Ponce Aix,S. Champiat,F-X. Danlos,C. Quevrin,A. Gazzah,R. Bahleda,E. Deutsch,A. Levy

ESMO Open（2023）

引用0浏览0引用

140P Stereotactic Radiotherapy Improves Disease Control in Oligoprogressive Patients Included in Early Clinical Trials, with Focus on NSCLC

A. Mavrikios,C. Baldini,Y. Loriot,S. Ponce Aix,S. Champiat,F-X. Danlos,C. Quevrin,A. Gazzah,R. Bahleda,E. Deutsch,A. Levy

Journal of thoracic oncologyno. 4 (2023): S119-S119

引用0浏览0引用

516P Building a New Prognostic Score for Patients with Central Nervous System (CNS) Tumors Enrolled in Early Phase Clinical Trials

K. Beshiri, A. Rousseau,S. Ponce Aix,S. N. Dumont,R. Bahleda,M. Touat,J-M. Michot,A. Hollebecque,A. Gazzah,K. Ouali,C. Henon,C. Smolenschi,F-X. Danlos,D. Guyon,S. Ammari,C. Massard,A. Marabelle,P. Martin Romano,S. Champiat,C. Baldini

Annals of Oncology (2023): S398-S398

引用0浏览0引用

Exclusion of Patients with Psychiatric Disorders from Early Phase Oncology Trials: A Limited Access to Innovation

P. Matte, M. Delaye, A. Mc Govern,K. Ouali,F-X. Danlos,C. Henon, V. Goldschmidt,L. Mahjoubi,A. Hollebecque,J-M. Michot,A. Gazzah,R. Bahleda,C. Smolenschi, A. Marabelle,S. Champiat,Y. Loriot,S. Ponce Aix,P. Rouby, C. Lemogne,C. Baldini

Annals of oncology (2023): S999-S1000

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn